Literature DB >> 9485373

Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin.

F A Baglia1, P N Walsh.   

Abstract

To study the physiological significance of thrombin as an initiator of intrinsic blood coagulation, activated human platelets were compared with dextran sulfate as a surface for thrombin-catalyzed factor XI activation. Activated gel-filtered platelets promoted factor XI activation by thrombin at initial rates 2-5-fold greater than dextran sulfate in the presence of high molecular weight kininogen (HK, 45 nM), ZnCl2 (25 microM), and CaCl2 (2 mM), conditions optimal for factor XI binding to platelets. Physiological concentrations of HK (636 nM) inhibited factor XI activation by thrombin in a concentration-dependent manner, and this inhibition was reversed by prothrombin (1-3 microM) and by prothrombin fragment 1.2 (PF1.2), but not by prothrombin fragment 1 (PF1). Since prothrombin and PF1.2 (but not PF1) also displaced HK from its binding site on the Apple 1 domain of factor XI, we conclude that the Kringle II domain of prothrombin competes with HK for binding to the Apple 1 domain of factor XI. Prothrombin (1-3 microM) and PF1.2 (but not PF1) in the presence of CaCl2 (2 mM) were able to replace HK (45 nM) in the presence of ZnCl2 (25 microM) as a cofactor for the specific, reversible, high-affinity (Kd approximately 25 nM) binding of factor XI to 947 +/- 150 sites per platelet. This binding is mediated by residues Asn 235-Arg 266 in the Apple 3 domain since a conformationally constrained, synthetic peptide analogue of this sequence inhibits both factor XI binding to activated platelets and platelet-mediated, thrombin-catalyzed factor XI activation in the presence of prothrombin and CaCl2. Finally, prothrombin (1.2 microM) and CaCl2 (2 mM) could substitute for HK (45 nM) and ZnCl2 (25 microM) in promoting optimal rates of thrombin-catalyzed factor XI activation on the platelet surface, thereby initiating the intrinsic coagulation pathway by mechanisms completely independent of the contact phase proteins, factor XII, HK, and prekallikrein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485373     DOI: 10.1021/bi972113+

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Crystal structure of Jararacussin-I: the highly negatively charged catalytic interface contributes to macromolecular selectivity in snake venom thrombin-like enzymes.

Authors:  A Ullah; T A C B Souza; L M Zanphorlin; R B Mariutti; V S Santana; M T Murakami; R K Arni
Journal:  Protein Sci       Date:  2013-01       Impact factor: 6.725

2.  Factor XI contributes to thrombin generation in the absence of factor XII.

Authors:  Dmitri V Kravtsov; Anton Matafonov; Erik I Tucker; Mao-Fu Sun; Peter N Walsh; Andras Gruber; David Gailani
Journal:  Blood       Date:  2009-04-07       Impact factor: 22.113

3.  Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.

Authors:  Tong Shi; G Michael Iverson; Jian C Qi; Keith A Cockerill; Matthew D Linnik; Pamela Konecny; Steven A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-08       Impact factor: 11.205

4.  A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets.

Authors:  Tara N Miller; Dipali Sinha; T Regan Baird; Peter N Walsh
Journal:  Biochemistry       Date:  2007-11-17       Impact factor: 3.162

5.  Feedback activation of factor XI by thrombin does not occur in plasma.

Authors:  Donna L Pedicord; Dietmar Seiffert; Yuval Blat
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-25       Impact factor: 11.205

Review 6.  An update on factor XI structure and function.

Authors:  Bassem M Mohammed; Anton Matafonov; Ivan Ivanov; Mao-Fu Sun; Qiufang Cheng; S Kent Dickeson; Chan Li; David Sun; Ingrid M Verhamme; Jonas Emsley; David Gailani
Journal:  Thromb Res       Date:  2017-10-10       Impact factor: 3.944

7.  Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer.

Authors:  Minwei Bao; Yuxia Huang; Zhongping Lang; Hui Zhao; Yuichi Saito; Tatsuya Nagano; Izumi Kawagoe; Duilio Divisi; Xiaoyi Hu; Gening Jiang
Journal:  Transl Lung Cancer Res       Date:  2022-07

Review 8.  Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders.

Authors:  Houssam Al-Koussa; Ibrahim AlZaim; Marwan E El-Sabban
Journal:  J Clin Med       Date:  2022-08-22       Impact factor: 4.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.